No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...

A new study suggests that high doses of vitamin D supplements could help reduce disease activity among multiple sclerosis ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps ...

Manuscript Summary Submission Deadline 30 May 2025 | Manuscript Submission Deadline 29 June 2025 | Manuscript Extension Submission Deadline 30 July 2025 ...